- Home
- Efficacy Studies
- EZ-PATH Results: LDL-C Efficacy
- EZ-PATH Results: Efficacy in Other Lipid Parameters
- EZ-PATH Results: Attainment of LDL-C <70 mg/dL
- EZ-PATH Results: Hypothetical Patient Case
- TEMPO Results: LDL-C Efficacy
- TEMPO Results: Efficacy in Other Lipid Parameters
- TEMPO Results: Attainment of LDL-C <100 mg/dL
- TEMPO Results: Hypothetical Patient Case
- Information About Titration
- Selected Statin Titration Studies
- Titration: 1-Year Retrospective Data
- Learn About ZETIA
- Multiple Studies
- Mechanism of Action
- LDL-C Efficacy of Monotherapy
- Coadministration With Fenofibrate
- LDL-C Efficacy: Patients Aged <65 and ≥65 Years
- Efficacy in Other Lipids
- Safety Profile, Tolerability, and Dosing
- Selected Safety Information
- Safety Profile and Tolerability: Patients Aged <65 and ≥65 Years
- Dosage: Once-Daily Tablet
- Clinical Studies
- Journal Reprints
- Managed Care Information
- Formulary Status
- Medicare Part D Formulary Status
- Physician Resources
- Merck OnCall ®
- eMedical Forums
- Request More Information
- Order Samples
- Patient Education Materials
- Prescribing Information
- Patient Information
- Patient Site for ZETIA
- Physician Site for VYTORIN® (ezetimibe / simvastatin)
This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.
For non-US health care professionals, click here.
ZETIA and VYTORIN are registered trademarks of MSP Singapore Company, LLC.
MerckMedicus™, MerckSource®, and MerckServices® are trademarks of Merck & Co., Inc.
Copyright © 2010 Merck/Schering-Plough Pharmaceuticals, a subsidiary of Merck & Co., Inc. All rights reserved.
21050228(1)-06/10-ZET